Hospital-acquired Pneumonia Drugs Market - Drivers and Forecasts by Technavio

Technavio has published a new report on the global HAP drugs market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global hospital-acquired pneumonia (HAP) drugs market to grow at a CAGR of more than 2% during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global HAP drugs market for 2017-2021. Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

HAP drugs belong to the wide spectrum of global infectious disease therapeutics market, which was valued at USD 150 billion in 2016. The global infectious disease drugs market can be broadly divided into several sub-markets with HAP drugs market being one of them. The global HAP market accounts for 2.81% of the global infectious disease drugs market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three factors that are contributing to the growth of the global HAP drugs market:

Unmet demand due to lack of available treatment for MDR microorganisms

Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.

Sapna Jha, a lead infectious and rare diseases research analyst at Technavio, says, “VAP patients have a very high chance of getting affected from MDR. There is a lack of proper treatment for these microorganisms; however, this can prove to be a big threat for the general population.”

Growing cases of surgeries

Nosocomial infections are one of the major challenges faced by the healthcare industry today. HAP is the second major type of nosocomial infections after urinary tract infections. The disease has the highest mortality rate of all other nosocomial infections and the rate ranges between 35% and 50%.

Organ transplant is done with the aim of restoring the functions of the body. Organ transplantation is many times the only treatment left at the end stage of organ failures such as heart or liver failure. The organ transplant process has rapidly increased during the last few years,” adds Sapna.

The inadequate healthcare infrastructure in the developing countries

Inadequate healthcare infrastructure and lack of proper hygiene are some of the major problems faced by the healthcare system of the developing countries. As a result, healthcare-associated infection is a point of concern for the developing countries. In most of the hospitals in the developing countries, infection control procedure and other hygienic necessities get influenced due to several factors such as poor infrastructure, lack of financial resources and overcrowded hospitals.

Top vendors:

  • GlaxoSmithKline
  • Merck
  • Mylan
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries

Browse Related Reports:

Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like oncology, vaccines, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio analysts forecast the global hospital-acquired pneumonia (HAP) drugs market to grow at a CAGR of more than 2% during the forecast period, according to their latest report.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com